Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASBU-SEPSIS trial of rasburicase for renal protection in sepsis
2023-508071-36-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2025
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis comparing Fasturtec with Placebo (2 arms). Primary endpoint: Worsening of renal function. Planned start Nov 2025; status: authorised.
02
Drugs
rasburicase
03
Conditions
sepsis
Beyond the preview
Go deeper on 2023-508071-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508071-36-00.